Cipla
Cipla Limited, a leading global pharmaceutical company headquartered in India, has been a pioneer in the healthcare industry since its establishment in 1935. With a strong presence in over 80 countries, Cipla focuses on developing a wide range of generic medicines, active pharmaceutical ingredients (APIs), and over-the-counter products. Renowned for its commitment to affordable healthcare, Cipla has made significant strides in areas such as respiratory, cardiovascular, and anti-retroviral therapies. The company is distinguished by its innovative approach to drug development and its robust pipeline of products, which cater to diverse therapeutic needs. Cipla's market position is bolstered by its extensive distribution network and strategic partnerships, making it a trusted name in the pharmaceutical sector. With numerous accolades for its contributions to global health, Cipla continues to lead the way in providing high-quality, accessible medicines.
DitchCarbon Score
How does Cipla's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cipla's score of 51 is higher than 68% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cipla's reported carbon emissions
In 2025, Cipla reported total carbon emissions of approximately 5,028,316,000 kg CO2e, with Scope 1 emissions at about 38,283,000 kg CO2e and Scope 2 emissions at approximately 129,087,000 kg CO2e. The company also disclosed significant Scope 3 emissions, including 2,660,995,000 kg CO2e from the use of sold products and 2,090,873,000 kg CO2e from purchased goods and services. Cipla has set ambitious climate commitments, aiming for carbon neutrality for its Scope 1 and Scope 2 emissions by December 2025. This goal is supported by initiatives to enhance energy efficiency and increase the use of renewable energy sources. Specifically, the company targets a 30% reduction in Scope 1 and Scope 2 emissions from 2020 levels by 2030. Additionally, they are working towards achieving near-zero emissions for these scopes by 2025. In India, Cipla's manufacturing operations are also focused on becoming carbon neutral by the end of 2025, with plans to utilise renewable energy and alternative fuels. These commitments reflect Cipla's proactive approach to addressing climate change and reducing its carbon footprint across its operations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 48,146,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 236,358,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cipla is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
